Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 7/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314209 | 0.86 | SCN5A (0.42) | SCN5AGRIN2BMAOAPSDPTGER4 | |
| SCHEMBL22314926 | 0.84 | SCN5A (0.40) | SCN5AGRIN2BMAOAPSDSCN1A | |
| SCHEMBL22314922 | 0.83 | TP53 (0.43) | SCN5AGRIN2BPSDTP53SCN1A | |
| SCHEMBL22314514 | 0.82 | SCN5A (0.45) | SCN5AGRIN2BPSDF2RL3NOTUM | |
| SCHEMBL22314213 | 0.82 | NPSR1 (0.42) | SCN5AGRIN2BMAOAPSDPTGER4 | |
| SCHEMBL22314208 | 0.82 | SCN5A (0.41) | SCN5AGRIN2BPSDTP53SCN1A | |
| SCHEMBL25865032 | 0.81 | SCN5A (0.44) | SCN5AGRIN2BMAOAPSDTNIK | |
| SCHEMBL22314548 | 0.81 | SCN5A (0.43) | SCN5AGRIN2BMAOAPSDTNIK | |
| SCHEMBL22314918 | 0.81 | SCN5A (0.52) | SCN5AGRIN2BPSDSCN1ASCN2A | |
| SCHEMBL22314912 | 0.81 | SCN5A (0.52) | SCN5AGRIN2BPSDTP53SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885GRIN2B 120/4885MAOA 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.